Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
第3相
実施中（募集終了）
NCT02842086
| 対象疾患 | Pre-Exposure Prophylaxis of HIV-1 Infection |
|---|
| 相 | 第3相 |
|---|
| スポンサー | Gilead Sciences |
|---|
| ステータス | 実施中（募集終了） |
|---|
| 参加者数 | 5,399 名 |
|---|
| 介入（薬剤） | F/TAF, F/TDF, F/TAF Placebo, F/TDF Placebo |
|---|
| 開始日 | 2016年9月2日 |
|---|
| 完了日 | 2019年1月31日 |
|---|
| 結果公開日 | 2020年3月17日 |
|---|
概要
The primary objective of this study is to assess the rates of HIV-1 infection in Men (MSM) and transgender women (TGW) who have sex with men and who are administered daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) with a minimum follow-up of 48 weeks and at least 50% of participants have 96 weeks of follow-up after randomization.
Incidence of HIV-1 Infection Per 100 Person Years (PY)
When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks) · HIV-1 infections per 100 PY
| Descovy (DVY) | 0.160 HIV-1 infections per 100 PY |
|---|
| Truvada (TVD) | 0.342 HIV-1 infections per 100 PY |
|---|
| Rate Ratio | 0.468 (95% CI 0.191–1.149) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。